Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Substrate selectivity and inhibition of the Pseudomonas aeruginosa MexXY efflux system

Award Number: F31AI203048
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 02/05/2027
PERIOD OF PERFORMANCE END DATE: 02/04/2028

Group Awards By:

View Award Description

Substrate selectivity and inhibition of the Pseudomonas aeruginosa MexXY efflux system - PROJECT SUMMARY/ ABSTRACT Antibiotic resistance is an increasing threat that contributes to ~5 million deaths worldwide every year. One common resistance mechanism among Gram-negative pathogens is the expression of Resistance-Nodulation- Division (RND) efflux systems that can pump antibiotics out of the cell. RND systems are tripartite complexes comprising an inner membrane transporter (e.g. MexY), a periplasmic adaptor protein (e.g. MexX), and an outer membrane protein (OMP; e.g. OprM). The opportunistic pathogen Pseudomonas aeruginosa encodes at least four RND systems that contribute to antibiotic resistance. Of these, MexXY-OprM is unique in its ability to efflux aminoglycosides, a class of antibiotics relied upon to treat serious P. aeruginosa infections. However, how substrates like aminoglycosides enter MexY and are thereby selected for efflux is unclear. Preliminary data suggest multiple potential entry points, and that these may be specific to the antibiotic class. Additionally, MexXY normally partners with OprM, but other OMPs (e.g. OpmB) can form functional complexes, potentially altering the substrate profile in ways that are not yet well defined. Determining the basis of MexXY substrate selectivity, both with its common OMP partner OprM and alternative OMPs, is a vital step toward developing effective efflux pump inhibitors (EPIs). The EPI candidate Ber-C3, a dimeric conjugate of the weak MexY inhibitor berberine, has enhanced EPI activity, but its mechanism of action is unknown. I hypothesize that antibiotic substrates and EPIs have specific entry points into MexY, and that these preferred transporter entry points are impacted by the substrate/inhibitor class and OMP partner. To test this hypothesis, I will determine the pathways of substrates and EPIs and the structural basis of selectivity and inhibition. In Aim 1, I will use Trp variants of MexY to block each entry channel and antibiotic susceptibility assays to identify the channel(s) used by each substrate. I will also generate strains with key MexY residues at the channel entries substituted to resemble MexB, the transporter of the MexAB-OprM system that effluxes β-lactams but not aminoglycosides. These assays will reveal key residues that impact distinct substrate selectivity between MexY and MexB. In Aim 2, I will use cryogenic electron microscopy (cryo-EM) to determine the first structures of MexXY-OprM and MexXY-OpmB with and without substrates. These high-resolution structures will reveal the structural basis for substrate selectivity and any allosteric effects the OMP has on MexY, potentially impacting selectivity. I will also use the Trp variants complemented with OpmB and perform MIC assays to determine whether the OMP identity impacts channel availability or substrate selectivity. In Aim 3, I will use cryo-EM to determine the structure of MexXY-OprM with Ber-C3 and thus the basis of its ability to inhibit efflux. I will also use the Trp variants to determine how Ber-C3 enters MexY and whether the OMP identity impacts Ber-C3 activity. These studies will deepen our understanding of RND pump structure and how they efflux antibiotics. Novel therapeutics are needed to combat growing antibiotic resistance and these insights will be invaluable in developing future EPIs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $50,114 )
2026	2026	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Allergy and Infectious Diseases Research	000	1	8/5/2026	NEW	$50,114
														Subtotal = $50,114

Grand Total All Awards = $50,114

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Substrate selectivity and inhibition of the Pseudomonas aeruginosa MexXY efflux system

Award Number: F31AI203048

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 02/05/2027

PERIOD OF PERFORMANCE END DATE: 02/04/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer